Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the First Half Ended June 30, 2019
July 05, 2019 at 02:11 am IST
Share
Shanghai Haohai Biological Technology Co., Ltd. provided group earnings guidance for the first half ended June 30, 2019. During the first half of 2019, the Group is expected to be operate smoothly and well. Taking account of the overall industry development and the Group's actual business performance, the company expects that the Group will record revenue in the range from approximately RMB 767.00 million to RMB 800.00 million, representing a year-on-year change of about 0.0% to 4.3%; profit attributable to owners of the parent company is expected to be in the range from approximately RMB 182.00 million to RMB 200.00 million, representing a year-on-year change of about -13.9% to -5.4%; and profit attributable to owners of the parent company after deducting non-recurring profit and loss is expected to be in the range from approximately RMB 180.00 million to RMB 198.00 million, representing a year-on-year change of about -10.2% to -1.2%.
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.